• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

Top Stories
A close-up of a mosquito feeding on a human Richard T. Nowitz / Getty Images

Google's parent company wants to release 32 million lab-altered mosquitoes in Florida and California — and the public's window to weigh in is closing

Two of the sunniest states on each coast of the US could soon also become among the buggiest of the bunch. Google’s parent company, Alphabet (NASDAQ: GOOG), is seeking federal approval to release up to 32 million specially treated mosquitoes across California and Florida over the next two years as part of a concerted effort to curb the spread of mosquito-borne diseases. But it sounds a lot itchier in planning than it would be in practice.

The proposal — submitted through Alphabet’s life science division, Verily, as part of its “Debug” initiative — is currently under review by the U.S. Environmental Protection Agency (EPA). Regulations.gov — the U.S. federal government site that essentially acts as an internet portal and document repository — released a notice in early May confirming the EPA’s receipt of an application from Google LLC, requesting an experimental use permit (EUP) for the “Wolbachia pipientis wAlbB,” which are contained in live adult Culex quinquefasciatus male mosquitoes.

Advertisement

“The Agency has determined that the permit may be of regional and national significance,” the notice reads. “Therefore, because of the potential significance, EPA is seeking comments on this application.”

The agency is accepting public comments through Friday, June 5 before deciding whether or not to grant an experimental use permit. Here’s what you should know about it.

What’s the point of releasing millions of mosquitoes?

The Debug project targets Culex mosquitoes, which can spread diseases including West Nile Virus (WNV) and St. Louis encephalitis (SLEV). According to the Centers for Disease Control and Prevention (CDC), WNV remains the most common mosquito-borne disease in the United States. The CDC also warns there are no vaccines to prevent or medications to treat neither WNV nor SLEV.

There have been more than 8,000 human cases and over 400 deaths due to WNV reported in California alone since 2003, according to the California Department of Public Health. While SLEV is less common, California public health officials are concerned it may be spreading.

Mosquito-borne illnesses are not just a California concern. Since its initial detection, human cases of WNV have been reported in every single US state except Alaska and Hawaii, according to the Florida Department of Health. There are at least 2,000 human cases of WNV every year, but because many people never develop symptoms, that number is likely an underestimate.

Verily’s Debug project aims to “make mosquito and disease reduction efforts more successful, and to make the Sterile Insect Technique more cost effective and accessible to more places affected by mosquito-borne diseases.” Unlike traditional mosquito-control methods that rely heavily on pesticides, the Sterile Insect Technique is a biological pest-control method that involves mass-rearing target insects and sterilizing them before releasing them into the wild to mate. The Debug project is attempting to automate that process with high precision.

Verily’s approach uses a naturally occurring bacterium called Wolbachia. Male mosquitoes infected with the bacteria are bred in laboratories and then released into the wild. When they mate with wild female mosquitoes, the resulting eggs fail to hatch, gradually reducing mosquito populations over time.

Here’s the key: Only male mosquitoes would be released, and because male mosquitoes do not bite humans, researchers say the project would not increase the number of biting insects that residents encounter. Hence why it wouldn’t be as itchy as it sounds.

A tried-and-true example

The technology is not entirely new. Verily has spent years developing automated mosquito-breeding systems that use artificial intelligence (AI), robotics and computer vision to sort mosquitoes by sex and scale production. And previous trials involving Wolbachia-infected mosquitoes have shown promising results in reducing mosquito populations.

Advertisement

In 2016, CMAD and MosquitoMate piloted the first-ever US release of male Aedes aegypti mosquitoes with Wolbachia in Fresno County, California. Verily collaborated with both groups in 2017 — on 25 times more mosquitoes. Verily trialed the release of 20 million mosquitoes to “collect the necessary evidence to bring [the plan] to a broader scale,” according to a blog post on the field study.

In early May, Debug also announced the expansion of its research and development (R&D) and mosquito production capabilities in Singapore, marking the establishment of the program’s first international R&D hub and its largest facility for adult mosquito production yet. The researchers found Singapore achieved 80-90% suppression of the Aedes aegypti mosquito population and more than 70% reduction in dengue incidents after just six to 12 months of releases.

The company says more than 10 million male Wolbachia mosquitoes are now released every single week in Singapore.

Must Read

Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.

What could go wrong with millions more mosquitoes?

Supporters argue innovative mosquito-control strategies are becoming increasingly important as invasive species expand their range and mosquito-borne illnesses become increasingly common. But not everyone is convinced. Some environmental groups have raised concerns about large-scale insect-release programs, arguing regulators should carefully study potential ecological impacts before approving widespread deployments.

Critics have also called for greater transparency about where releases would occur and how success of such initiatives would be measured.

If approved, the experiment would release approximately 16 million mosquitoes during the first year and another 16 million during the second year. Regulators have not yet disclosed which Florida or California communities could be selected as release sites.

The bottom line

There is no publicly disclosed budget for the current Debug proposal, so any estimate is speculative for now. What we do know, however, is that Verily launched the initiative specifically because traditional methods of combating mosquito-borne diseases are considered massively labor-intensive and too expensive to scale. Verily has spent years building automated breeding, sex-sorting and release systems to make the process simpler and more scalable.

Given that this is a multi-state pilot backed by Alphabet — and that it involves tens of millions of mosquitoes — a reasonable ballpark estimate could very well be in the millions over the lifetime of the project. But researchers beg the question: Could spending millions on mosquito suppression ultimately save millions more in healthcare costs, mosquito-control costs and disease prevention?

You May Also Like

Share this:
AnnaMarie Houlis Weekend Editor

AnnaMarie is a weekend editor for Moneywise.

more from AnnaMarie Houlis

Explore the latest

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither investment, tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities, enter into any loan, mortgage or insurance agreements or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter. Advertisers are not responsible for the content of this site, including any editorials or reviews that may appear on this site. For complete and current information on any advertiser product, please visit their website.

†Terms and Conditions apply.